This year, the EMJ GOLD team were live on the ground at EHA 2026 to speak with industry leaders about the latest developments shaping the future of haematology
Interview by Helena Bradbury
In this interview, hear from Ester in ’t Groen, Therapeutic Area Head, Haematology, Johnson & Johnson Innovative Medicine EMEA, as she discusses how advances in T-cell redirecting therapies are transforming the treatment landscape for multiple myeloma.
Reflecting on the significant progress made over the past two decades, in ’t Groen explores the growing impact of bispecific antibodies and CAR-T cell therapies, highlighting how these innovations are extending survival and offering new possibilities for patients with relapsed disease.
The conversation covers a range of topics, including the shift towards earlier use of bispecific therapies, the potential of combination approaches with established treatments and the importance of delivering personalised treatment strategies for patients with multiple myeloma.
In ’t Groen also shares her perspective on the future of haematology, emphasising the rapid pace of innovation across the field and the collective ambition to develop increasingly effective therapies that bring the goal of eliminating cancer ever closer.
Guest bio
Ester in ’t Groen is Therapeutic Area Head, Haematology, Johnson & Johnson Innovative Medicine EMEA. In this role, she is responsible for the medical strategy for the haematology therapeutic area across Europe, the Middle East and Africa, overseeing the development and implementation of regional medical affairs strategies while contributing to the global strategy for innovations in blood cancer treatment.
In ’t Groen joined Johnson & Johnson in 2011 and has held a number of leadership positions across oncology and haematology. Most recently, she served as Country Medical Director for the Netherlands, overseeing the Dutch Medical Department across therapeutic areas. She has also held roles including EMEA Medical Director CAR-T and several regional and local haematology medical affairs positions across the Netherlands, Benelux and EMEA regions, with particular experience in multiple myeloma and CAR-T cell therapy.
Prior to joining Johnson & Johnson, in ’t Groen completed a Master’s degree in Biomedical Health Sciences and a PhD in Cell Biology at Radboud University Nijmegen before working in clinical research at Pfizer and Covance.
